{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EBV+specific+CTL+Infusion&page=2", "query": { "intervention": "EBV specific CTL Infusion", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EBV+specific+CTL+Infusion&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-24T13:58:54.172Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01570283", "title": "ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Viral Infection" ], "interventions": [ { "name": "Multivirus-specific T cells Dose Level 1", "type": "BIOLOGICAL" }, { "name": "Multivirus-specific T cells Dose Level 2", "type": "BIOLOGICAL" }, { "name": "Multivirus-specific T cells Dose Level 3", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AlloVir", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 21, "start_date": "2012-09", "completion_date": "2017-09", "has_results": true, "last_update_posted_date": "2019-05-30", "last_synced_at": "2026-09-24T13:58:54.172Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01570283" }, { "nct_id": "NCT02108522", "title": "Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Infection" ], "interventions": [ { "name": "Multivirus Specific T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AlloVir", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 82, "start_date": "2014-06", "completion_date": "2019-12", "has_results": true, "last_update_posted_date": "2021-07-20", "last_synced_at": "2026-09-24T13:58:54.172Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02108522" }, { "nct_id": "NCT02057445", "title": "3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkins Lymphoma", "Hodgkins Lymphoma", "Lymphoproliferative Disorder" ], "interventions": [ { "name": "EBV CTL's", "type": "DRUG" }, { "name": "Peripheral Blood Donor", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "New York Medical College", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 1, "start_date": "2014-01", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2017-12-22", "last_synced_at": "2026-09-24T13:58:54.172Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Valhalla, New York", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02057445" }, { "nct_id": "NCT00889954", "title": "Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2 Positive Malignancies" ], "interventions": [ { "name": "TGFBeta resistant HER2/EBV-CTLs", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 20, "start_date": "2009-05", "completion_date": "2018-01-21", "has_results": false, "last_update_posted_date": "2018-09-18", "last_synced_at": "2026-09-24T13:58:54.172Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00889954" }, { "nct_id": "NCT01498484", "title": "Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "EBV-induced Lymphomas", "EBV-associated Malignancies", "Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma" ], "interventions": [ { "name": "EBV-specific T cells (EBV-CTLs)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Atara Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 87, "start_date": "2011-12", "completion_date": "2019-07", "has_results": true, "last_update_posted_date": "2022-10-21", "last_synced_at": "2026-09-24T13:58:54.172Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01498484" }, { "nct_id": "NCT01475058", "title": "CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia", "Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Mantle Cell Lymphoma", "Refractory Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "allogeneic cytomegalovirus-specific cytotoxic T lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1, "start_date": "2012-04", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2017-02-15", "last_synced_at": "2026-09-24T13:58:54.172Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01475058" }, { "nct_id": "NCT02065362", "title": "TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "EBV-positive Nasopharyngeal Carcinoma" ], "interventions": [ { "name": "DNR.NPC-specific T cells", "type": "BIOLOGICAL" }, { "name": "DNR.NPC-specific T cells + cyclophosphamide + fludarabine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 14, "start_date": "2015-02", "completion_date": "2033-02", "has_results": false, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-09-24T13:58:54.172Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02065362" }, { "nct_id": "NCT01535885", "title": "Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Epstein-Barr Virus Infections", "Adenovirus", "Cytomegalovirus Infections" ], "interventions": [ { "name": "Cytotoxic T Lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "22 Years", "sex": "ALL", "summary": "Up to 22 Years" }, "enrollment_count": 25, "start_date": "2012-02", "completion_date": "2019-10", "has_results": false, "last_update_posted_date": "2021-10-25", "last_synced_at": "2026-09-24T13:58:54.172Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01535885" }, { "nct_id": "NCT00002663", "title": "Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "EBV-induced Lymphomas", "EBV-associated Malignancies", "Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma" ], "interventions": [ { "name": "Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Atara Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 58, "start_date": "1995-03", "completion_date": "2019-07", "has_results": true, "last_update_posted_date": "2023-02-13", "last_synced_at": "2026-09-24T13:58:54.172Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002663" }, { "nct_id": "NCT01070797", "title": "Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenovirus Infection", "Epstein-Barr Virus Infections", "Cytomegalovirus Infections", "Stem Cell Transplant" ], "interventions": [ { "name": "Multi-virus Specific T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 10, "start_date": "2011-01", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2014-09-04", "last_synced_at": "2026-09-24T13:58:54.172Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01070797" } ] }